Bovine Tissue Product Trio Could Flesh Out Tutogen's Xenograft Offerings
This article was originally published in The Gray Sheet
Executive Summary
A 510(k) application that would allow Tutogen Medical to market xenograft bovine pericardium tissue for neurological use will be one of three submissions the company intends to file with FDA by the second quarter of 2001.
You may also be interested in...
Sulzer Buys Paragon Anticipating Increased Conversion To Dental Implants
Anticipating increased conversion of the tooth replacement market to dental implants from conventional treatments such as bridges and crowns, Sulzer Medica is paying about 3.3 times sales to acquire dental implant maker Core Vent Corporation/Paragon Implant Company. The move roughly doubles Sulzer's share of the $550 mil. dental implant market to about 10.5%.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.